{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihbl3ia3juvlikopvvujn3tg3mwx7p4pou332eby4avui2xqwcfka",
    "uri": "at://did:plc:vv5cq7qjnr2fd5ytohsyyegf/app.bsky.feed.post/3mntbwhnvp7f2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreia6r6qa4utm7o37wwvtfibzywhmwlxxtnp6u73zy3365daoteypbq"
    },
    "mimeType": "image/jpeg",
    "size": 179700
  },
  "path": "/2026/06/breast-cancer-genomic-test-could-spare-millions-from-chemotherapy/",
  "publishedAt": "2026-06-08T00:00:15.000Z",
  "site": "https://www.optimistdaily.com",
  "tags": [
    "Evergreen",
    "Gender",
    "Health",
    "Medicine",
    "Science",
    "Technology",
    "Trending",
    "ASCO 2026",
    "breast cancer",
    "breast cancer genomic test",
    "breast cancer treatment 2026",
    "Cancer Research",
    "Chemotherapy",
    "gene test breast cancer",
    "Genomics",
    "Medical Breakthroughs",
    "oncology",
    "OPTIMA trial",
    "Prosigna breast cancer",
    "skip chemotherapy breast cancer",
    "women's health",
    "Breast cancer genomic test could spare millions from chemotherapy",
    "The Optimist Daily: Making Solutions the News"
  ],
  "textContent": "BY THE OPTIMIST DAILY EDITORIAL TEAM For decades, high clinical risk and chemotherapy arrived together as a package deal in early breast cancer. A trial presented at the American Society of Clinical Oncology meeting in Chicago on May 30, 2026, is pulling them apart. The OPTIMA trial enrolled more than 4,400 patients across the United […]\n\nThe post Breast cancer genomic test could spare millions from chemotherapy first appeared on The Optimist Daily: Making Solutions the News.",
  "title": "Breast cancer genomic test could spare millions from chemotherapy"
}